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Abstract
Background: Breast cancer patients with estrogen receptor (ER)–positive disease have a continuous long-term risk for fatal
breast cancer, but the biological factors influencing this risk are unknown. We aimed to determine whether high intratumor
heterogeneity of ER predicts an increased long-term risk (25 years) of fatal breast cancer.
Methods: The STO-3 trial enrolled 1780 postmenopausal lymph node–negative breast cancer patients randomly assigned to
receive adjuvant tamoxifen vs not. The fraction of cancer cells for each ER intensity level was scored by breast cancer pathol-
ogists, and intratumor heterogeneity of ER was calculated using Rao’s quadratic entropy and categorized into high and low
heterogeneity using a predefined cutoff at the second tertile (67%). Long-term breast cancer-specific survival analyses by in-
tra-tumor heterogeneity of ER were performed using Kaplan-Meier and multivariable Cox proportional hazard modeling
adjusting for patient and tumor characteristics.
Results: A statistically significant difference in long-term survival by high vs low intratumor heterogeneity of ER was seen for
all ER-positive patients (P < .001) and for patients with luminal A subtype tumors (P ¼ .01). In multivariable analyses, patients
with high intratumor heterogeneity of ER had a twofold increased long-term risk as compared with patients with low intratu-
mor heterogeneity (ER-positive: hazard ratio [HR] ¼ 1.98, 95% confidence interval [CI] ¼ 1.31 to 3.00; luminal A subtype tumors:
HR¼2.43, 95% CI¼1.18 to 4.99).
Conclusions: Patients with high intratumor heterogeneity of ER had an increased long-term risk of fatal breast cancer.
Interestingly, a similar long-term risk increase was seen in patients with luminal A subtype tumors. Our findings suggest that
intratumor heterogeneity of ER is an independent long-term prognosticator with potential to change clinical management,
especially for patients with luminal A tumors.
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Article
Breast cancer is the most common cancer in women, with an es-
timated 1 million new cases and more than 400 000 deaths annu-
ally worldwide (1). It is a diverse disease, both in the sense of the
metastatic potential of the primary tumor and in time for metas-
tasis to occur (2), occasionally spanning more than 20 years be-
tween primary tumor diagnosis and metastasis. Endocrine
therapy is a cornerstone in the management of estrogen recep-
tor–positive (ER) breast cancer and has improved patient survival
considerably (3). However, approximately 50% of patients with
ER-positive disease fail to respond to endocrine therapy, and ap-
proximately one out of four women with early-stage breast can-
cer will later develop distant metastatic disease (4,5).
The biological factors influencing the long-term risk of fatal
breast cancer are unknown. It is, however, known that patients
with ER-positive disease have a continuous long-term risk for fa-
tal breast cancer, in contrast to patients with ER-negative cancer
(4). It has been suggested that late fatal disease mechanisms may
involve cancer cells staying dormant over a long period of time
(6). Given the late onset of fatal disease in ER-positive breast can-
cer and the lack of clinical studies with long-term follow-up, it is
difficult to predict who has a high long-term risk of fatal disease.
We and others have shown that ER expression in primary
breast cancer tumors is altered throughout tumor progression,
which influences patient survival (7,8). It has further been sug-
gested that breast cancers possess intratumor heterogeneity
with varying metastatic capacity (9–11). We hypothesized that
patient long-term survival is dependent on the degree of intra-
tumor heterogeneity of ER. Using a large Swedish clinical trial
with complete long-term (25 years) follow-up of patients ran-
domly assigned to receive adjuvant tamoxifen vs not, we inves-
tigated whether intratumor heterogeneity of ER is associated
with an increased long-term risk of fatal breast cancer.
Methods
The Stockholm Tamoxifen Trial
The Stockholm Breast Cancer Study Group conducted random-
ized trials from 1976 onwards (12,13). The Stockholm Tamoxifen
Trial (STO-3) trial enrolled 1780 postmenopausal patients from
1976 until 1990 with lymph node–negative breast cancers with
tumors smaller than or equal to 30 mm in diameter, randomly
assigned to two years of adjuvant tamoxifen (40 mg daily) vs no
adjuvant treatment. In 1983, patients who reconsented and
were relapse-free after 2 years of tamoxifen treatment were
randomized to 3 additional years of tamoxifen or no further
therapy. The STO-3 trial was approved by the ethical committee
at Karolinska Institutet, and participants provided oral consent.
At the time when the trial was approved and started, written
consent was not considered ethically acceptable by the ethical
committees in Sweden, but was thought to disturb the trustful
patient-doctor relationship; therefore only oral consent was ac-
cepted and practiced.
The patient subset with formalin-fixed paraffin-embedded
(FFPE) material available is well balanced to the original STO-3
trial cohort with regards to tumor characteristics, such as tumor
size (78% vs 81%), ER status (78% vs 80%), and treatment arm as-
signment (52% vs 50%) (Supplementary Material, available on-
line) (14). All patients included in the STO-3 randomized trial
have detailed patient and clinical information.
In Sweden, all residents have a unique national registration
number, which enables automatic linkage of various records of
personal information from national registers of high validity
and essentially complete coverage. Death due to breast cancer
was assessed from the Swedish National Cause-of-Death
Register with a reported accuracy of more than 96% from
January 1, 1961, and onwards (15,16). The information on cause
of death is from death certificates filled in by treating physi-
cians. Furthermore, information on contralateral breast cancer
was assessed from the Swedish National Cancer Registry.
Cancer registration has a legal basis in Sweden, and the
Swedish Cancer Registry has breast cancer coverage of more
than 96% in validation studies (17). Finally, the Swedish
National Total Population Register holds different types of infor-
mation on individuals including information on emigration
from Sweden and has high validity and completeness (18). Thus
given the Swedish national registers, patients in the STO-3 trial
had complete long-term follow-up until December 31, 2012.
ER, Progesterone Receptor, Human Epidermal Growth
Factor Receptor 2, and Ki-67
We first assigned all available FFPE tumor blocks a random order
of annotation. In 2014, the FFPE tumors were sectioned at 4 lm
and mounted on plus coated glass slides in the Tissue Profiling
Facility at the Science for Life Laboratory at Uppsala University.
Patient whole-tumor sections were sent to the University of
California Davis Medical Center (UCDMC) CLIA laboratory, and im-
munohistochemistry (IHC) was done for ER, progesterone receptor
(PR), human epidermal growth factor receptor 2 (HER2), and Ki-67
(Supplementary Material, available online). The majority of the
IHC-stained slides (approximately 90%) were assessed as being of
high quality (with high RNA quality as mentioned below).
Ten pathologists (RB, JB, PC, YC, BD, FH, GK, FL, YZ, and
AB) at the University of California with expertise in breast diag-
nostics, as a part of the ATHENA Breast Health network, scored
(on whole-tumor sections with microscopes) the percentage of
positive breast cancer cells for each ER intensity level (0, þ1, þ2,
orþ 3) compared with established standards, after completing
an online training module developed to standardize the distinc-
tions between intensity levels (Supplementary Material, avail-
able online) (19). In addition, the pathologists scored the
percentage of cancer cells positive for PR, HER2, and Ki-67,
where a threshold of 10% or greater was used to define ER and
PR receptor positivity, HER2 positivity was defined as intensity
3þ by immunohistochemistry, and the Ki-67 threshold for posi-
tivity was 15% or greater. The ER H-Score is defined as the sum
of the percentage of ER-positive tumor cells at each intensity
level multiplied by an ordinal value corresponding to the inten-
sity level (0 ¼ none, 1 ¼weak, 2 ¼moderate, and 3 ¼ strong).
Intratumor Heterogeneity of ER
We used Rao’s quadratic entropy to quantify intratumor hetero-
geneity of ER within each patient tumor. The Simpson index is
one of the most commonly used diversity measurements and
has previously been used to assess clonal diversity and genomic
intratumor heterogeneity in cancer (20–22). Rao’s quadratic en-
tropy (QE; continuous score) (23,24) uses the Simpson index (22)
together with a distance matrix as weights to better quantify
intratumor heterogeneity. In our study, the proportions in the
Simpson index are defined by the proportion of tumor cells pos-
itively stained for ER at each intensity level (þ0, þ1, þ2, orþ 3).
The distance matrix used as weights reflects the difference in
ER intensity. For instance, a difference between ER intensity 0þ
and 3þ within a tumor would be weighted as a 3, whereas a
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difference between ER intensity 1þ and 2þ within a tumor
would be weighted as a 1 (Supplementary Material, available
online).
The predefined cutoff at the second tertile (67%) for high
intratumor heterogeneity was used in order for a smaller propor-
tion of the tumors to be defined with this characteristic (high
intratumor heterogeneity), in agreement with other tumor char-
acteristics such as PR status and Ki-67 (25). We refer to these cat-
egories as high and low intratumor heterogeneity of ER.
Tumor Grade
Tumor grade according to the Nottingham system was retro-
spectively assessed by one pathologist (14).
Intrinsic Subtypes (PAM50)
Gene expression data were generated using custom-designed
Agilent arrays containing approximately 32.1K probes, repre-
senting approximately 21.5K unique genes from FFPE breast
cancer tumor tissue. Approximately 90% (or 652 breast cancer
tumors) passed the RNA quality check (according to the diag-
nostic quality model) and were used in the intrinsic subtype
analysis. Tumors were assigned to one of five molecular sub-
types (luminal A, luminal B, HER2-enriched, basal-like, normal-
like) using the PAM50 classifier, as described in Parker et al.
(Supplementary Material, available online) (26).
Statistical Methods
Differences in patient and tumor characteristics between high
and low intratumor heterogeneity of ER were tested with the
Fisher exact test. The intratumor heterogeneity (QE, continuous
score) of luminal A and luminal B tumors was contrasted using
a Kernel density plot overlaying the distributions.
The outcome of interest was death due to breast cancer, and
analyses of long-term breast cancer–specific survival (25 years)
by intratumor heterogeneity of ER were performed. We included
patients with ER-positive breast cancer because intratumor het-
erogeneity of ER is not meaningful in ER-negative cancer.
Patient follow-up started at the date of primary breast cancer di-
agnosis and ended at the date of death, contralateral breast can-
cer diagnosis, emigration from Sweden (only five women
emigrated), or end of study follow-up (December 31, 2012).
Kaplan-Meier analyses were performed for high and low
intratumor heterogeneity of ER by STO-3 trial arm (four groups:
low heterogeneity/treated arm, low heterogeneity/untreated
arm, high heterogeneity/treated arm, high heterogeneity/
untreated arm) for all patients and for patients with luminal A
subtype tumors. Subset analyses for patients with luminal B
tumors were not performed because the sample sizes were too
small for long-term survival analyses. Statistical significance
was assessed using the log-rank test.
Multivariable analysis for high intratumor heterogeneity,
with low intratumor heterogeneity as the reference category,
was performed using Cox proportional hazard modeling, adjust-
ing for the classical patient and tumor characteristics, that is,
all the available standard variables known to be important for
breast cancer survival (such as age and calendar period of breast
cancer diagnosis, ER-positive stained cells [%], ER H-Score, PR
status, HER2 status, Ki-67 status [15% used as positive cutoff],
tumor grade, tumor size, and STO-3 trial arm). HER2 status was
not adjusted for in the subgroup analysis (tamoxifen-treated,
untreated, and luminal A) due to the small number of HER2-
positive patients.
The proportional hazard assumption for intratumor hetero-
geneity was assessed using a time-by-covariate interaction (be-
tween intratumor heterogeneity and follow-up time). No
statistically significant interaction was noted. An arbitrary level
of 5% statistical significance (two-tailed) was used. All data
preparation and analysis were done using SAS version 9.4 and R
version 3.2.1. All statistical tests were two-sided, and a P value
of less than .05 was considered statistically significant.
Results
Intratumor Heterogeneity of ER
Patient and tumor characteristics by intratumor heterogeneity
of ER are presented in Table 1, and the STO trial consort diagram
is presented in Supplementary Figure 1 (available online).
Intratumor heterogeneity (low vs high) was well balanced, and
no patient or tumor characteristic as tested was statistically sig-
nificantly associated with intratumor heterogeneity (Table 1).
The cutoff value for high intratumor heterogeneity was prede-
fined to be at the second tertile (67%) of the continuous Rao’s
quadratic entropy score, which was at 0.855. Thus, the low
intratumor heterogeneity category was defined as less than
0.855 (including only positive values), and high intratumor het-
erogeneity was defined as 0.855 or greater (maximum value was
1.395). In Supplementary Figure 2 (available online), patient
tumors according to low/high intratumor heterogeneity of ER
and ER H-Score are presented. In tumors with high intratumor
heterogeneity of ER, the percentage of ER-positive tumor cells
ranged from 20% to 100% (Supplementary Figure 3A, available
online). Similarly, tumors with high intratumor heterogeneity
of ER had a large span of H-Scores (Supplementary Figure 3B,
available online).
We investigated whether high intratumor heterogeneity of ER
was more predominant in the luminal B subtype, which is gener-
ally considered an aggressive characteristic as compared with lu-
minal A, using a Kernel density plot overlaying the distributions
(QE, continuous score). However, a very similar distribution of
intratumor heterogeneity of ER was observed (Figure 1). Indeed,
approximately one-third of the tumors were of high intratumor
heterogeneity of ER regardless of luminal A or luminal B subtype
(Table 1), and no statistically significant association was observed
between luminal A and luminal B tumor subtype, and high vs low
intratumor heterogeneity (Fisher exact test, P¼ .26).
Long-term Breast Cancer–Specific Survival Analysis
Univariate Survival Analysis
We performed Kaplan-Meier analysis by intratumor heteroge-
neity of ER and trial arm (four groups: low heterogeneity/treated
arm, low heterogeneity/untreated arm, high heterogeneity/
treated arm, high heterogeneity/untreated arm). A statistically
significant difference in long-term survival was seen (log-rank,
P < .001) (Figure 2A). Patients with low intratumor heterogeneity
of ER in the tamoxifen-treated arm had excellent survival (25-
year breast cancer–specific survival, 88.3%), followed by treated
patients with high intratumor heterogeneity (79.6%), untreated
patients with low intratumor heterogeneity (74.3%), and lastly
untreated patients with high intratumor heterogeneity (64.3%).
In addition, Kaplan-Meier analysis including patients with lumi-
nal A subtype tumors (by intratumor heterogeneity of ER and
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trial arm; four groups) was performed. A statistically significant
difference in long-term survival by intratumor heterogeneity and
trial arm was also seen for luminal A patients, together with a
similar survival graph pattern by intratumor heterogeneity and
trial arm, as described above (log-rank, P¼ .01) (Figure 2B).
Multivariable Survival Analysis
Multivariable analysis of breast cancer–specific survival by
intratumor heterogeneity of ER was performed using Cox
proportional hazard modeling, adjusting for classical patient
and tumor characteristics (such as age and calendar period of
breast cancer diagnosis, ER-positive stained cells [%], ER H-
Score, PR status, HER2 status, Ki-67 status, tumor grade, tumor
size, and STO trial arm), as well as the crude estimates (only
adjusting for age and period at breast cancer diagnosis).
Patients with high intratumor heterogeneity of ER had an ap-
proximately twofold increased long-term risk of fatal breast
cancer disease as compared with patients with low heterogene-
ity (hazard ratio [HR] ¼ 1.98, 95% confidence interval [CI] ¼ 1.31
Table 1. Patient and tumor characteristics at primary breast cancer diagnosis by intratumor heterogeneity of ER
STO-3 trial
Low heterogeneity High heterogeneity
P* Total No. of patientsNo. (%) No. (%)
STO-3 trial arm .93
Tamoxifen-treated arm 205 (51.6) 102 (52.0) 307
Untreated arm 192 (48.4) 94 (48.0) 286
Patient characteristics
Calendar period of primary diagnosis .80
1976–1979 59 (14.9) 33 (16.8) 92
1980–1984 146 (36.8) 69 (35.2) 215
1985–1990 192 (48.3) 94 (48.0) 286
Age at primary diagnosis, y .71
45–54 43 (10.8) 17 (8.7) 60
55–64 199 (50.1) 98 (50.0) 297
65–74 155 (39.1) 81 (41.3) 236
Primary tumor characteristics
Type of surgery .53
Breast-conserving surgery and RT 93 (23.4) 41 (20.9) 134
Mastectomy 304 (76.6) 155 (79.1) 459
Progesterone receptor status .92
Positive 266 (68.4) 131 (67.9) 397
Negative 123 (31.6) 62 (32.1) 185
Unknown 8 3 11
HER2 status† 1.00
Positive 17 (4.3) 8 (4.1) 25
Negative 378 (95.7) 187 (95.9) 565
Unknown 2 1 3
Ki-67 status‡ .06
Positive 90 (23.8) 30 (16.6) 120
Negative 288 (76.2) 151 (83.4) 439
Unknown 19 15 34
Tumor grade .52
1 86 (21.9) 44 (22.9) 130
2 248 (63.1) 126 (65.6) 374
3 59 (15.0) 22 (11.5) 81
Unknown 4 4 8
Tumor size, mm .36
pT< 20 319 (81.2) 164 (84.5) 483
pT 20 74 (18.8) 30 (15.5) 104
Unknown 4 2 6
Intrinsic subtypes (PAM50) .21
Basal 6 (1.6) 1 (0.6) 7
HER2-enriched 17 (4.7) 4 (2.3) 21
Luminal A 233 (64.0) 103 (59.2) 336
Luminal B 80 (22.0) 46 (26.4) 126
Normal-like 28 (7.7) 20 (11.5) 48
Unknown 33 22 55
*Two-sided Fisher exact test. ER ¼ estrogen receptor; HER2 ¼ human epidermal growth factor receptor 2; RT ¼ radiotherapy; STO-3 ¼ Stockholm Tamoxifen trial 3.
†HER2 positive defined as 3þ by immunohistochemistry.
‡Ki-67 cutoff for positivity at 15%.
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to 3.00) (Table 2). The hazard ratio effects for all covariates in
the model (crude and adjusted) are presented in Supplementary
Table 1 (available online). Competing risk analysis using Fine-
Gray regression modeling yielded very similar results (data not
shown).
Furthermore, analysis in each trial arm revealed a 2.2-fold
and 1.9-fold increased risk of fatal breast cancer in the tamoxi-
fen-treated and untreated arms, respectively, for patients with
high intratumor heterogeneity of ER compared with patients
with low heterogeneity (tamoxifen-treated arm: HR ¼ 2.15, 95%
CI ¼ 1.07 to 4.34, and untreated arm: HR ¼ 1.91, 95% CI ¼ 1.12 to
3.27) (Table 2). Finally, in patients with luminal A subtype
tumors, a more than twofold risk of fatal breast cancer was seen
for patients with high intratumor heterogeneity of ER compared
with patients with low heterogeneity (HR ¼ 2.43, 95% CI ¼ 1.18
to 4.99) (Table 2).
Discussion
In this study, we investigated whether high intratumor hetero-
geneity of ER is associated with an increased long-term risk of
fatal breast cancer. Our findings indicate that intratumor het-
erogeneity of ER is an independent prognosticator for long-term
breast cancer–specific survival. Notably, intratumor heteroge-
neity of ER was also associated with long-term fatal breast can-
cer risk in patients with luminal A subtype, as patients with
high intratumor heterogeneity of ER had a statistically signifi-
cant and marked increased risk of fatal breast cancer.
It is widely recognized that primary breast cancer tumors
possess intratumor heterogeneity that may give rise to cells
with varying metastatic capacity (9,10). More recently, we and
others have shown that the clinically used breast cancer
markers alter their expression throughout tumor progression
(8), and genetic studies have shown that metastases may arise
from a minority of cells within the primary tumor (11,27,28).
Indeed, our findings that high intratumor heterogeneity of ER is
associated with poor breast cancer–specific survival are consis-
tent with the notion that tumors with high intratumor hetero-
geneity may harbor cells with the capacity to metastasize
because of the cells’ capacity to adapt over time and under ther-
apeutic pressure.
Patients with ER-positive disease, including those with low-
risk node-negative disease, have a limited early risk but a con-
tinuous long-term risk for fatal breast cancer (3,4,29–31). It is
clear that classical tumor characteristics such as lymph node
status and tumor size can predict early risk, but it remains con-
troversial how to identify the patients at later risk. Lymph node
positivity, grade, and high expression of genes involved in the
ER-signaling pathways have, however, been suggested to be im-
portant for late breast cancer disease (32–34). Moreover, the ob-
servation that patients with high intratumor heterogeneity of
ER had a continuous risk for fatal breast cancer up to 25 years,
at end of follow-up, in our study suggests that intratumor het-
erogeneity of ER may be useful as a long-term breast cancer–
specific survival predictor.
The continuous long-term risk for patients with ER-
positive disease has been suggested to involve cancer cells
staying dormant over long periods of time. Even for patients
with low-stage disease, micrometastases in the bone marrow
are not uncommon (35), and circulating breast cancer tumor
cells have been found even 20 years after diagnosis in patients
who are clinically disease free (36). From these and other
observations, it is clear that more knowledge about tumor dor-
mancy and how to maintain the balance between tumor cell
growth and tumor cell death is needed. Indeed, given that ER-
positive disease is associated with an increased long-term risk
of fatal disease, one may hypothesize that having dormant tu-
mor cells with different ER expression levels, as compared
with more homogeneous ER expression, may influence patient
survival.
We retrospectively analyzed the STO-3 trial, a trial of tamox-
ifen vs no taxomifen from 1976 until 1990, enabling long-term
analysis of breast cancer survival (12,13). Because the clinical
management and treatment has changed over time, our study
shares the same limitations with other long-term follow-up
studies (4). The STO-3 trial was performed before aromatase
inhibitors were developed; the duration of tamoxifen therapy
was shorter than currently recommended, and we lack informa-
tion on treatment at relapse. Approximately half of the patients
from the original trial cohort had tumor blocks available for mo-
lecular analysis and were thus included in our study. We con-
firmed, however, that patient and tumor characteristics in our
study were equally distributed between the arms and well bal-
anced to the original STO-3 cohort with regards to characteris-
tics such as tumor size, ER status, and treatment arm
assignment (14). Finally, assessments of IHC markers are known
to vary; however, in our study, ER (together with PR, HER2, and
Ki-67) was recently, in 2014, stained at a single medical center
laboratory and assessed by experienced breast cancer patholo-
gists who had been harmonized with regard to the scoring of
IHC markers, including ER.
In conclusion, patients with high intratumor heterogene-
ity of ER have statistically significantly worse long-term sur-
vival as compared with patients with low intratumor
heterogeneity. Interestingly, intratumor heterogeneity of ER
also identified patients at increased long-term risk for fatal
breast cancer in patients with luminal A subtype tumors, gen-
erally considered to be a low-risk group. Intratumor heteroge-
neity of ER should be easy to translate into clinical routine
given that ER is assessed for every newly diagnosed breast
cancer patient. Importantly, routine clinical assessment of
intratumor heterogeneity of ER may identify ER-positive
breast cancer patients at high long-term risk for fatal breast
cancer, which could change clinical management, especially
for patients with luminal A subtype tumors. Finally, future
Figure 1. Kernel density plot of the intratumor heterogeneity of the estrogen re-
ceptor (quadratic entropy QE, continuous score) for luminal A vs luminal B sub-
type tumors (PAM50). ER ¼ estrogen receptor.
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validation of our findings in prospective studies with long-
term follow-up and ER-stained slides available is warranted
and planned.
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